JPAD-Journal of Pakistan Association of Dermatologists. 2014; 24 (2): 122-126
em En
| IMEMR
| ID: emr-196843
Biblioteca responsável:
EMRO
Objective: To evaluate the efficacy of combined therapy of meglumine antimoniate and co-trimoxazole in cutaneous leishmaniasis [CL]
Methods: 180 patients with active lesions of CL, confirmed by fine needle aspiration cytology [FNAC] were treated with combined therapy of meglumine antimoniate [Glucantime] and co-trimoxazole [Septran] for 20 days
Results: Out of 180 patients, 160 [88.9%] were cured. A few patients reported nausea, vomiting, glossitis, skin rashes and folate deficiency
Conclusion: The combined therapy of meglumine antimoniate [Glucantime] and co-trimoxazole [Septran] is more effective than the previously reported combined therapies
Methods: 180 patients with active lesions of CL, confirmed by fine needle aspiration cytology [FNAC] were treated with combined therapy of meglumine antimoniate [Glucantime] and co-trimoxazole [Septran] for 20 days
Results: Out of 180 patients, 160 [88.9%] were cured. A few patients reported nausea, vomiting, glossitis, skin rashes and folate deficiency
Conclusion: The combined therapy of meglumine antimoniate [Glucantime] and co-trimoxazole [Septran] is more effective than the previously reported combined therapies
Buscar no Google
Índice:
IMEMR
Idioma:
En
Revista:
J. Pak. Assoc. Dermatol.
Ano de publicação:
2014